Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

296 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Design of a prospective, longitudinal cohort of people living with type 1 diabetes exploring factors associated with the residual cardiovascular risk and other diabetes-related complications: The SFDT1 study.
Riveline JP, Vergés B, Detournay B, Picard S, Benhamou PY, Bismuth E, Bordier L, Jeandidier N, Joubert M, Roussel R, Sola-Gazagnes A, Bonnefond A, Clavel S, Velayoudom FL, Beltrand J, Hanaire H, Fontaine P, Thivolet C, Servy H, Tubiana S, Lion S, Gautier JF, Larger E, Vicaut E, Sablone L, Fagherazzi G, Cosson E. Riveline JP, et al. Among authors: roussel r. Diabetes Metab. 2022 May;48(3):101306. doi: 10.1016/j.diabet.2021.101306. Epub 2021 Nov 21. Diabetes Metab. 2022. PMID: 34813929
Allelic variations of the vitamin D receptor (VDR) gene are associated with increased risk of coronary artery disease in type 2 diabetics: the DIABHYCAR prospective study.
Ferrarezi DA, Bellili-Muñoz N, Dubois-Laforgue D, Cheurfa N, Lamri A, Reis AF, Le Feuvre C, Roussel R, Fumeron F, Timsit J, Marre M, Velho G. Ferrarezi DA, et al. Among authors: roussel r. Diabetes Metab. 2013 May;39(3):263-70. doi: 10.1016/j.diabet.2012.11.004. Epub 2013 Jan 23. Diabetes Metab. 2013. PMID: 23352876
Morning administration of 0.4U/kg/day insulin glargine 300U/mL provides less fluctuating 24-hour pharmacodynamics and more even pharmacokinetic profiles compared with insulin degludec 100U/mL in type 1 diabetes.
Bailey TS, Pettus J, Roussel R, Schmider W, Maroccia M, Nassr N, Klein O, Bolli GB, Dahmen R. Bailey TS, et al. Among authors: roussel r. Diabetes Metab. 2018 Feb;44(1):15-21. doi: 10.1016/j.diabet.2017.10.001. Epub 2017 Nov 16. Diabetes Metab. 2018. PMID: 29153485 Free article. Clinical Trial.
Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes.
Ritzel R, Roussel R, Bolli GB, Vinet L, Brulle-Wohlhueter C, Glezer S, Yki-Järvinen H. Ritzel R, et al. Among authors: roussel r. Diabetes Obes Metab. 2015 Sep;17(9):859-67. doi: 10.1111/dom.12485. Epub 2015 Jun 16. Diabetes Obes Metab. 2015. PMID: 25929311 Free PMC article.
Decreased insulin secretion and increased risk of type 2 diabetes associated with allelic variations of the WFS1 gene: the Data from Epidemiological Study on the Insulin Resistance Syndrome (DESIR) prospective study.
Cheurfa N, Brenner GM, Reis AF, Dubois-Laforgue D, Roussel R, Tichet J, Lantieri O, Balkau B, Fumeron F, Timsit J, Marre M, Velho G. Cheurfa N, et al. Among authors: roussel r. Diabetologia. 2011 Mar;54(3):554-62. doi: 10.1007/s00125-010-1989-0. Epub 2010 Dec 3. Diabetologia. 2011. PMID: 21127832
296 results